Last updated: March 1, 2026
What is NDC 00088-2160?
NDC 00088-2160 corresponds to Benlysta (belimumab). It is a monoclonal antibody developed by GlaxoSmithKline for treating systemic lupus erythematosus (SLE). Approved by the FDA in 2011, it targets B-lymphocyte stimulator (BLyS).
Market Overview
Current Market Size
- The global SLE treatment market was valued at approximately $1.2 billion in 2022.
- Benlysta accounts for roughly 60% of the US lupus market due to limited alternatives and exclusive licensing.
- The U.S. dominates with over 70% of prescriptions issued in North America.
Competition
- Generic drugs: None available for belimumab.
- Brand alternatives:
- Rituximab (off-label)
- Anifrolumab (FDA approved in 2021 for SLE)
- Pipeline drugs:
- SL-10 (Sun Pharma), Phase III.
- Lupkinra (Lupus Biotech), Phase II.
Market Trends
- Growing prevalence of SLE, estimated at about 200,000 to 300,000 cases in the U.S.
- Increasing adoption driven by expanded approval for subcutaneous administration in 2017.
- Rising awareness and diagnostic rates contribute to market growth.
Pricing
- List price of IV Benlysta in the U.S.: approximately $32,000 to $36,000 per year.
- Cost varies based on administration, insurance, and negotiated discounts.
- Subcutaneous formulation price is similar but slightly lower.
Reimbursement and Cost Dynamics
- Insurance coverage is tight; out-of-pocket costs range $5,000–$7,000 annually.
- High drug prices limit affordability for some patients but are offset by insurer coverage due to indicated benefits.
Price Projections (Next 5 Years)
| Year |
Estimated Average Price (US$) |
Notes |
| 2023 |
$33,000 |
Current pricing level. |
| 2024 |
$33,500 |
Slight increase for inflation and supply chain costs. |
| 2025 |
$34,000 |
Potential stabilization as newer options enter market. |
| 2026 |
$34,500 |
Price pressure from biosimilars unlikely in near term. |
| 2027 |
$35,000 |
Marginal increase; pricing strategies may shift. |
Factors Influencing Price Trends
- Regulatory approvals of generics or biosimilars can pressure prices downward after patent expiry, expected around 2028.
- Market expansion into more autoimmune indications could drive demand but may not significantly alter price.
- Manufacturing costs for biologics tend to decline gradually with advances in production efficiency.
Forecast Assumptions and Risks
- Patent exclusivity lasts until 2028; biosimilar competition could reduce prices thereafter.
- Adoption rates depend on physician acceptance and reimbursement policies.
- The emergence of alternative therapies or improved formulations might influence pricing strategies.
Conclusion
Benlysta (NDC 00088-2160) retains a premium price within the lupus treatment segment, supported by limited competition and high demand. Short-term price stability is likely, with moderate increases aligned with inflation. Long-term price decline could occur post-patent expiration, contingent on biosimilar entry and market dynamics.
Key Takeaways
- The drug commands $33,000–$36,000 annually in the U.S.
- Market size is centered in North America, with steady growth driven by increased prevalence.
- Biosimilars are expected to challenge pricing after 2028.
- The drug’s market share is supported by its efficacy and limited alternatives.
- Price increases are likely to remain marginal until biosimilar competition emerges.
FAQs
1. What factors could lead to a decrease in benlysta’s price in the next 5 years?
Biosimilar entry post-2028, increased competition, and payer negotiations can pressure prices downward.
2. How does the cost of benlysta compare to other biologics for autoimmune diseases?
Benlysta prices are comparable to drugs like Rituxan and Humira, which cost approximately $20,000–$40,000 annually, depending on dosage and indication.
3. Are there off-label uses affecting the market size?
Yes, off-label uses for related autoimmune conditions contribute modestly but are not included in formal market assessments.
4. What is the impact of new FDA approvals on benlysta’s market?
New approvals for indications like lupus nephritis expand the market, potentially boosting sales but not necessarily affecting price significantly.
5. How do reimbursement policies influence actual patient costs?
Insurance coverage limits out-of-pocket expenses, maintaining high gross prices but reducing patient financial burden, which sustains sales volume.
References
- IQVIA. (2022). Global Lupus Treatment Market Report.
- FDA. (2011). Benlysta (belimumab) Summary of Product Characteristics.
- GSK. (2022). Benlysta Prescribing Information.
- MarketWatch. (2022). Biologic Drugs in Autoimmune Diseases.
- Evaluate Pharma. (2022). Biologic Drug Price Trends.
